Skip to main content
. Author manuscript; available in PMC: 2008 Nov 23.
Published in final edited form as: Neuroscience. 2007 Aug 28;149(4):768–778. doi: 10.1016/j.neuroscience.2007.08.025

Figure 5.

Figure 5

Effect of VDCC blockers on evoked and delayed release in APP−/− and WT NMJs. A-C. Representative traces showing evoked and delayed release triggered by 30 pulse-stimulation at 200 Hz in the absence of blockers (Ctrl), with 1 μM ω-CgTx-GVIA (A, N-blocker), 20 μM nifedipine (B, L-blocker) or 100 nM ω-Agatoxin-IVA (C-D, P/Q-blocker) Scale: 5 mV/50 msec. D - E. Bar diagrams illustrate the blockade exerted by ω-CgTx-GVIA (WT, N=5; APP−/−, N=11), nifedipine (WT, N=5; APP−/−, N=6) or ω-Agatoxin-IVA (WT, N=5; APP−/−, N=8) on evoked, delayed release and 1st EPP amplitude in APP−/− and WT controls. Error bars indicate SEM. *p<0.05.